[ad_1]
Gilead takes the turn, first quarter earnings up 28%
Gilead Sciences (GILD) First Quarter Results ($ M): Sales: 5281 (+ 3.8%); product: 5200 (+ 4.0%). HIV sales up 12.5% to $ 3.6 billion. HCV sales down 21% to $ 790 million. Key …
View full coverage on Google News
[ad_2]
Source link